Jun 04, 2020
Targovax Enters Collaboration With Leidos to add Checkpoint Inhibitor Functionality to ONCOS Viruses
Apr 27, 2020
Valo Therapeutics to Support Development of a Pan - Coronavirus Vaccine
Apr 22, 2020
Targovax and Valo Therapeutics Enter Collaboration to Develop RAS Neoantigen Coating of ONCOS Viruses Using PeptiCRAd Technology
Feb 06, 2020
Valo Therapeutics Announces New Funding for Immuno-Oncology Trials
Jan 13, 2020
DNAtrix Appoints Jeff Knapp as Chief Executive Officer and to Board of Directors
Nov 28, 2019
WuXi ATU and GeneMedicine Sign Development and Manufacturing Agreement for Oncolytic Virus Products
Nov 24, 2019
DNAtrix Presents Positive Results from the Phase 2 CAPTIVE/KEYNOTE-192 Study of DNX-2401 in Combination with Pembrolizumab for Glioblastoma at the 2019 SNO Annual Meeting
Nov 11, 2019
DNAtrix to Present Updated Results from the Phase 2 CAPTIVE / KEYNOTE-192 Study of DNX-2401 in Combination with Pembrolizumab for Glioblastoma at the 2019 SNO Annual Meeting
Sep 02, 2019
Valo Therapeutics Acquires PeptiENV Technology from the University of Helsinki
Jun 17, 2019
Valo Therapeutics Appoints Michael Stein as Chief Executive Officer
Apr 30, 2019
Tessa Therapeutics, in Collaboration with Baylor College of Medicine, Presents Preclinical Results Showing Enhanced T Cell Responses Against HER2-Positive Solid Tumors Using Novel Combination CAR T Cell Therapy
Nov 26, 2018
Alcyone Lifesciences Announces the Use of AMC Intratumoral Delivery Platform in the Treatment of First Patient in DNX-2440 Glioblastoma Trial
Nov 13, 2018
DNAtrix and Valo Therapeutics Enter into Strategic Partnership to Develop Peptide-Coated Oncolytic Viruses for Treating Cancer
Nov 07, 2018
Effectiveness of DNAtrix's DNX-2440 Oncolytic Virus Expressing OX40L in Solid Tumors to be Presented at the 2018 Annual Meeting of the Society for Immunotherapy of Cancer
Sep 12, 2018
Targovax Announces Publication of New Oncolytic Virus Data in the Journal of Medical Virology and Cancer Gene Therapy
Jul 12, 2018
Targovax and SOTIO Announce First Patient Dosed in Phase I/II Combination Trial of ONCOS-102 With DCVAC
Jun 11, 2018
Targovax Strengthens Focus on ONCOS Oncolytic Virus Development Program
May 10, 2018
Vyriad to Build State-of-the-Art Facility for Manufacturing Oncolytic Virus Anti-Cancer Vaccines in Rochester, Minn.
May 08, 2018
Successful Delivery of DNAtrix's Oncolytic Virus DNX-2401 to Pediatric Brain Tumors
Apr 12, 2018
Effectiveness of DNAtrix Oncolytic Virus DNX-2440 Armed with OX40L to be Presented at the 2018 Annual Meeting of the American Association for Cancer Research